← Patent-cliff monitor small molecule LIVTENCITY MARIBAVIR
Loss of exclusivity October 2043 latest FDA-listed patent expiry
Company TAKEDA PHARMACEUTICALS USA INC
Drug detail Brand name LIVTENCITY Active ingredient MARIBAVIR Strength 200MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval November 2021 Marketing status RX
Listed patents Patent Expires Type 12295940 October 2043 substance, product 12527771 October 2043 substance, product 12433907 November 2042 use U-4289 12447170 November 2042 use U-4328 12213989 November 2042 use U-4137 11684632 January 2032 use U-3650 12661368 October 2031 use U-4572 12447169 October 2031 use U-4329
Regulatory exclusivity Code Expires ODE-388 November 2028 NCE November 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.